Moleculin Biotech Inc

NASDAQ:MBRX   3:59:52 PM EDT
2.68
+0.02 (+0.75%)
Products

Moleculin Receives FDA Approval Of Fast Track Designation For Annamycin In The Treatment Of Sarcoma Lung Metastases

Published: 03/30/2021 12:18 GMT
Moleculin Biotech Inc (MBRX) - Moleculin Receives FDA Approval of Fast Track Designation for Annamycin in the Treatment of Sarcoma Lung Metastases.